WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH NEWS

Warptech News aggrega le notizie più rilevanti da oltre 150 fonti internazionali, con classificazione AI e timeline cluster su singole storie.

Navigazione

Home
Archivio
Cerca
Il tuo account

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Amgen files update to Tavneos label as FDA escalates push to withdraw — Warptech News

Amgen files update to Tavneos label as FDA escalates push to withdraw

Amgen has taken steps to update its Tavneos label amid an ongoing battle with the FDA.

venerdì 1 maggio 2026 New tab

78 words~1 min read

May 1, 2026 09:02 AM EDTUpdated 03:04 PM

Amgen files update to Tavneos label as FDA escalates push to withdraw

Amgen has taken steps to update its Tavneos label amid an ongoing battle with the FDA.

The company filed a supplement …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Other newsrooms on this story

· 3 sources

Full timeline →

biopharmadive.com·May 6, 2026 · 10 g fa
Avalo shares spike on skin drug data; BioNTech to cut staff
statnews.com·May 1, 2026 · 15 g fa
Axsome wins FDA nod for Alzheimer's agitation
ynetnews.com·Apr 29, 2026 · 17 g fa
Teva resumes acquisitions with $900 million Emalex deal after decade-long hiatus

Related reading

Amgen expands crackdown on what it says is misuse of 340B program

Amgen is expanding its claims data requirements for pharmacies dispensing its drugs under the 340B federal drug discount program.

endpoints.news·1 g fa

Ipsen pulls cancer drug from market over safety risks

The committee reported cases of hematologic malignancies in a follicular lymphoma study dubbed SYMPHONY-1.

endpoints.news·2 mesi fa

Atara, Pierre Fabre will get another shot at FDA approval, a week after…

US regulators are willing to reconsider using a Phase 3 study of tab-cel as the basis for an approval, after previously rejecting…

endpoints.news·9 g fa

biopharmadive.com

Avalo shares spike on skin drug data; BioNTech to cut staff

Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close…

biopharmadive.com·10 g fa

biopharmadive.com

Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers

Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its…

biopharmadive.com·1 g fa

FDA to reconsider treatment for rare cancer after its surprise rejection

The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.

statnews.com·9 g fa